Protocol · Eating pattern
Non-sugar sweeteners (aspartame-centred class record)
B
Headline grade
Sweeteners in this class are safe at intakes within the acceptable daily intakes
Evidence type: Mixed evidence
The graded dose: Aspartame at the centre of the class; the graded frame is intake against the acceptable daily intakes. At the JECFA and EFSA acceptable daily intake of 40 mg/kg body weight, a 70 kg adult’s ceiling is 2,800 mg of aspartame a day; a 12-ounce diet soda carries roughly 180 to 200 mg, so the ceiling sits near 14 cans a day, every day. Typical consumption is a small fraction of the acceptable daily intake in every national survey. Frequency in the evidence: Daily. The grade attaches to this dose; below it, the grade does not apply.
Build this protocol: see Non-sugar sweeteners (aspartame-centred class record) assembled and graded, then adjust it to your goals.
Time cost
0 minutes / week
No session time; sweeteners substitute inside ordinary eating and drinking.
Dollar cost
Free
No standalone cost is graded: the record grades a substitution inside ordinary foods and drinks, not a product bought on its own. (basis: substitution, not a purchase)
Every claim, graded
Each outcome this protocol is claimed to deliver carries its own grade and its own kind of evidence. A strong secondary outcome never launders a weak popular claim: the popular claim prints at its own grade, next to the headline.
Outcomes at a glance
Aspartame increases cancer risk at normal dietary intakes
Sweeteners in this class are safe at intakes within the acceptable daily intakes
Non-sugar sweeteners help with weight control
Saccharin and sucralose impair glucose tolerance through the gut microbiome
Sucralose is genotoxic (the sucralose-6-acetate claim)
Erythritol raises cardiovascular risk (the sugar-alcohol claim, adjacent class)
Stevia and monk fruit are the safe natural alternatives (the absence-of-signal claim)
Bar length is the outcome's evidence grade on the house scale: A is 4.0 points, B is 3.0, C is 2.0, D is 1.0. The table below carries the evidence type and what the data show for each row.
| Claim | Grade | Evidence | What the data show |
|---|---|---|---|
| Aspartame increases cancer risk at normal dietary intakes | D+ | mixedMixed evidence | Not supported at dietary exposure. IARC's July 2023 Group 2B classification (possibly carcinogenic) rests on limited evidence for hepatocellular carcinoma in a small number of cohorts and is a hazard classification, made without reference to dose. On the same evidence, JECFA found the cancer link not convincing and reaffirmed the acceptable daily intake of 0 to 40 mg/kg, and the FDA publicly disagreed with IARC. No study demonstrates increased cancer risk at intakes below the ADI; the grade prices the dietary claim, and the classification itself is reported in full wherever this record is cited.IARC Monographs, aspartame evaluation, July 2023 (Group 2B, limited evidence, hepatocellular carcinoma).; JECFA, aspartame evaluation, July 2023 (ADI 0 to 40 mg/kg body weight reaffirmed).; FDA response to the IARC classification, July 2023. |
| Sweeteners in this class are safe at intakes within the acceptable daily intakes | B | mixedMixed evidence | The regulatory convergence is unusually complete: JECFA, EFSA, and the FDA independently maintain ADIs for aspartame, sucralose, saccharin, acesulfame-K, and the steviol glycosides, and national intake surveys consistently find typical consumption at a small fraction of them. The arithmetic for the centre compound: at 40 mg/kg, a 70 kg adult's aspartame ceiling is 2,800 mg a day, roughly 14 cans of diet soda, every day. What the grade does not carry is lifetime randomized safety data, which does not exist for any food additive at this scale; the B prices convergent regulatory review plus exposure arithmetic, stated as such.JECFA and EFSA ADI determinations for the class compounds.; National dietary intake surveys as summarised in the regulatory reviews (typical intakes a small fraction of ADIs). |
| Non-sugar sweeteners help with weight control | C+ | rctRandomized trials | A modest, real substitution effect that the two loudest readings both overstate. Short-term randomized trials (the WHO 2023 review's 283-study base) show small weight reductions when sweeteners replace sugar. The first large long trial, SWEET (Nature Metabolism 2025; 341 adults after a weight-loss phase), found the sweetener group maintained 1.6 kg more weight loss at one year than the sugar group (P = 0.029), with no cardiometabolic differences; attrition was 40 percent and some authors report sweetener-industry fees, both stated. WHO's conditional recommendation against using sweeteners for weight control rests on low-certainty evidence and on cohort associations it acknowledges may be reverse causation. Net: replacing sugar helps modestly, including at one year in one large trial; sweeteners are not themselves a weight-loss intervention, and the cohort harm signal is unresolved rather than established.WHO, Use of non-sugar sweeteners: guideline and commissioned systematic review, 2023 (283 studies; conditional recommendation, low certainty).; Pang MD et al., the SWEET study, Nature Metabolism 2025;7:2083-2098 (341 adults; 1.6 kg maintenance advantage at 1 year; NCT04226911). |
| Saccharin and sucralose impair glucose tolerance through the gut microbiome | C- | rctRandomized trials | One well-run randomized trial (Suez et al., Cell 2022; 120 adults, 2 weeks at below-ADI doses) found saccharin and sucralose worsened glycaemic responses in a subset of participants, mediated by personalised microbiome changes; aspartame and stevia did not in the same trial. The effect is short-term, person-specific, and unreplicated at scale, and SWEET's year-long class-level exposure found no adverse glycaemic signal. A live hypothesis with one strong small trial behind it, graded at exactly that weight.Suez J et al., Cell 2022 (personalised microbiome-mediated glycaemic effects of saccharin and sucralose).; Pang MD et al., SWEET, Nature Metabolism 2025 (no glycaemic difference at one year). |
| Sucralose is genotoxic (the sucralose-6-acetate claim) | D | mixedMixed evidence | An in-vitro and rodent claim, not a human finding: a 2023 study reported genotoxicity signals for sucralose-6-acetate (an impurity and metabolite) at concentrations whose relevance to dietary exposure is contested, and regulators reviewing the same work did not change sucralose's status. No human study shows genotoxic harm at dietary doses. The claim circulates at a strength its evidence form cannot carry, and the record grades the claim as circulated, not the compound's overall file (which the ADI outcome above prices).Schiffman SS et al., Journal of Toxicology and Environmental Health B, 2023 (sucralose-6-acetate in-vitro and rodent findings).; Regulatory responses maintaining sucralose's ADI, 2023. |
| Erythritol raises cardiovascular risk (the sugar-alcohol claim, adjacent class) | C- | mixedMixed evidence | The class's strongest open question, graded as open. The Cleveland Clinic programme (Witkowski et al., Nature Medicine 2023) associated circulating erythritol with major cardiovascular events across three cohorts (adjusted hazard ratios 1.80 and 2.21, top against bottom quartile), and its intervention work (2024) showed a single 30 g drink raising plasma erythritol more than 1,000-fold and increasing platelet aggregation in every subject, against a null glucose arm. The unresolved confounds are structural: the body produces erythritol endogenously in proportion to metabolic dysfunction, so the cohort marker may track the disease rather than the diet; the intervention dose was one concentrated drink on an empty stomach; and no outcome trial exists. The FDA reviewed the work and left erythritol's status unchanged. A replicated mechanism plus a confounded association is a signal to watch, not a verdict in either direction.Witkowski M et al., Nature Medicine 2023;29:710-718 (cohorts and pilot intervention).; Witkowski M et al., Arteriosclerosis, Thrombosis, and Vascular Biology 2024 (30 g erythritol against glucose; platelet reactivity).; FDA evaluation of the erythritol findings (associational; status unchanged). |
| Stevia and monk fruit are the safe natural alternatives (the absence-of-signal claim) | C | mixedMixed evidence | Their regulatory files are real (steviol glycosides carry an ADI of 4 mg/kg as steviol equivalents; monk fruit extract is GRAS) and their human outcome files are thin in both directions: no demonstrated harm at dietary doses and no demonstrated benefit beyond replacing sugar, which the weight outcome above already prices. Natural origin is not an evidence category; these grade at C on convergent regulatory review with low evidence weight, the same standard the synthetic compounds are held to in this record.EFSA and JECFA steviol glycoside evaluations (ADI 4 mg/kg as steviol equivalents).; FDA GRAS notices for monk fruit (luo han guo) extracts. |
Dose and response
A hazard classification states what a substance can do at some dose; the grades in this record price what the evidence shows at dietary doses, inside the acceptable daily intakes. Below those intakes the safety claim grades B; the harm claims grade on their own files at the same doses.
Equipment that can deliver this dose: none.
Harms and cautions
Harms live in this ledger, not inside the grade: the grade is evidence for the claimed outcomes in the studied population.
Medication interactions
No medication classes are flagged in this graded record.
Goal conflicts and timing
No goal conflicts in this record.
Timing is not graded: the record grades a substitution across the day’s eating and drinking, not a scheduled intake.
Population exclusions and other cautions
None recorded.
Can you measure it yourself?
No self-experiment is offered for this record's headline outcomes. Class record drafted 2026-11-15 (pulled forward under the full-day rule) from research/sweeteners-assembly-2026-11-14.md and its Sunday continuation. Aspartame at the centre; each sweetener graded as a claim set inside one record. The record's spine is the hazard-versus-risk distinction: a hazard classification states what a substance can do at some dose; the grades below price what the evidence shows at dietary doses.
Goals served
None at the serving floor
Derived from outcomes grading B- or better, never hand-assigned.
Experience gate
beginner and up (gated for safety)
Applicability
broad
Applies broadly, across goals and populations.
Grades are research summaries, not medical advice. Decisions about your own stack belong with your clinician.
Longevity Lab Report
Protocol news. Graded when it happens.
The grades on this page stay free. The email is the week's longevity and biohacking news in plain English: expert moves, what is working, and new supplements and peptides, each story linked to the grades on this site.
Frequently asked questions
What grade does Non-sugar sweeteners (aspartame-centred class record) get?
At the studied dose (Aspartame at the centre of the class; the graded frame is intake against the acceptable daily intakes. At the JECFA and EFSA acceptable daily intake of 40 mg/kg body weight, a 70 kg adult’s ceiling is 2,800 mg of aspartame a day; a 12-ounce diet soda carries roughly 180 to 200 mg, so the ceiling sits near 14 cans a day, every day. Typical consumption is a small fraction of the acceptable daily intake in every national survey.), Non-sugar sweeteners (aspartame-centred class record) grades B for sweeteners in this class are safe at intakes within the acceptable daily intakes, on mixed evidence. The grade attaches to that dose; below it, the grade does not apply.
How much time does Non-sugar sweeteners (aspartame-centred class record) take each week?
At the graded dose: No session time; sweeteners substitute inside ordinary eating and drinking. Dollar cost: No standalone cost is graded: the record grades a substitution inside ordinary foods and drinks, not a product bought on its own..
Sources
- Research sweeteners assembly and Sunday continuation (research/sweeteners-assembly-2026-11-14.md), with the WHO guideline, the erythritol programme, and the SWEET trial read in full. (2026)
Changelog
Last reviewed November 15, 2026
- 2026-11-15|Graded draft filed (Research): the sweeteners class record, aspartame at the centre, graded as claim sets; the hazard-versus-risk distinction is the record's stated spine. Pending cold read and Growth integration.